"Eye Doctors Ophthalmic Consultants of the Capital Region provides a comprehensive model of eye care with experienced specialists, ophthalmologists, optometrists, and opticians providing patient-centered eye expertise in Albany, Clifton Park, Schenectady, Schodack, and Troy. Our seasoned eye doctors take the time to get to know you, your medical history, and your vision and lifestyle needs. Whether you are visiting us to treat a common eye condition or you have a more serious eye disorder, know that we endeavor to provide the highest standard of comprehensive eye care services with excellence and compassion that will consistently exceed your expectations."

During the past decade, Ophthalmic Consultants of the Capital Region conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ophthalmic Consultants of the Capital Region" #1 collaborator was "Regeneron Pharmaceuticals" with 1 trials as a collaborator and "Trial Runners, LLC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Ophthalmic Consultants of the Capital Region" are "Neovascular Age-Related Macular Degeneration" (1 trials), "Neovascular Age-related Macular Degeneration" (1 trials) and "Retinopathy, Diabetic" (1 trials). Many other conditions were trialed in "Ophthalmic Consultants of the Capital Region" in a lesser frequency.

Most popular intervention types in "Ophthalmic Consultants of the Capital Region" are "Drug" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials), "OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)" (1 trials) and "Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ophthalmic Consultants of the Capital Region" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Ophthalmic Consultants of the Capital Region". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Ophthalmic Consultants of the Capital Region, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ophthalmic Consultants of the Capital Region, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".